# Low Dose IL2 Immunotherapy in AD

> **NCT05821153** · PHASE1 · COMPLETED · sponsor: **The Methodist Hospital Research Institute** · enrollment: 8 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Aldesleukin

## Key facts

- **NCT ID:** NCT05821153
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-19
- **Primary completion:** 2022-04-27
- **Final completion:** 2022-04-27
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05821153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05821153, "Low Dose IL2 Immunotherapy in AD". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05821153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*